透過您的圖書館登入
IP:34.227.191.136
  • 學位論文

探討靈芝免疫調節蛋白抑制肺癌細胞之Wnt/β-catenin訊息傳遞路徑

Down-regulation of Wnt/β-catenin signaling pathway in lung cancer cells by GMI, an immunomodulatory protein from Ganoderma microsporum

指導教授 : 柯俊良

摘要


在Wnt訊息路徑中,β-catenin為訊息傳遞路徑中重要的調節蛋白,其穩定性與入核現象被視為路徑活化的關鍵。Wnt訊息路徑所調控下游基因之表現與細胞存活、細胞侵襲和細胞抗藥性有密切關係。本實驗將探討在肺癌細胞是否藉由小孢子靈芝免疫調節蛋白(Fungal immunomodulatory protein- Ganoderma microsporum,GMI) 抑制Wnt訊息路徑之β-catenin表現量。經西方墨點法發現,GMI可有效抑制β-catenin蛋白表現量,並由核質分離法可發現GMI會抑制H1355細胞核和與細胞質的β-catenin蛋白量。以TOPFLASH/FOPFLASH reporter assay,GMI具有抑制β-catenin/Tcf 轉錄活性。RT-PCR與Real-time PCR結果發現,GMI具降低β-catenin下游基因cyclin-D1與survivin表現。透過CCK-8方法與流式細胞儀偵測GMI抑制肺癌細胞之細胞存活現象並促使細胞死亡。以Wnt3a刺激細胞可增加β-catenin蛋白而減少cleaved caspase 7,反之,將β-catenin基因關閉則可增加cleaved caspase 7表現。分別以MG132或LLnL (proteasome inhibitor) 或SB216763 (p-GSK3β抑制劑)處理細胞可抑制 GMI將β-catenin降解。在非小細胞肺癌中,具EGFR突變細胞具有高表現的β-catenin蛋白量。在EGFR雙重突變L858R/T790M細胞H1975對於GMI敏感,GMI可有效減少β-catenin,而以ICG-001 (Wnt/β-catenin/TCF 基因轉錄抑制劑,且專一結合於element-binding protein (CBP)) 可增加細胞死亡。本研究結果顯示,GMI可抑制β-catenin的表現進而抑制Wnt/β-catenin路徑與癌細胞增生,在EGFR雙重L858R/T790M突變細胞H1975也具有明顯的抑制效果,因此未來將進一步分析GMI抑制β-catenin後的下游基因表現與癌症增生的關係。

並列摘要


β-catenin play a central role in Wnt signaling pathway. Aberrant activation of Wnt/β-catenin signaling downstream genes, such as survivin, c-myc, cyclin D involved in cell resistant, cell survival and cell invasion. In this study, we investigated the effects of GMI, a recombinant fungal immunomodulatory protein from Ganoderma microsporum on β-catenin/Tcf signaling, apoptosis induction and β-catenin/Tcf transcription activity in lung cancer. Lung cancer cells were treated with GMI for cell viability and cell apoptosis measured by CCK-8 assay and flow cytometry analysis. Nuclear and cytoplasmic β-catenin protein level were inhibited by GMI analyzed on Western blot. In addition, proteasome inhibitors MG132 and LLnL or p-GSK3β inhibitors SB216763 prevented the degradation of β-catenin mediated by GMI. Stimulation of Wnt3a induced β-catenin and reduced cleaved caspase 7. Knockdown of β-catenin gene expression elevated cleaved caspase 7. GMI decreased β-catenin/Tcf transcription activity by TOPFLASH/FOPFLASH reporter assay. Survivin and cyclin D1 have been down-regulated by GMI on RT-PCR and real time PCR. Furthermore, NSCLC patients with epidermal growth factor receptor gene mutant had high expression of β-catenin. Our findings indicate that GMI can decrease β-catenin expression and induces cell death in H1975 (EGFR L858R/T790M mutate) lung cancer cells. GMI might be therapeutic agent targeting to EGFR-double mutation H1975 lung cancer cells. In conclusion, our data demonstrated that GMI reduced β-catenin and inhibits the Wnt signaling pathway in non-small cell lung cancer (NSCLC).

參考文獻


Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-57
Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-804
Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA (2009) Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28: 2163-72
Atkinson JM, Rank KB, Zeng Y, Capen A, Yadav V, Manro JR, Engler TA, Chedid M (2015) Activating the Wnt/beta-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One 10: e0125028
Bazley LA, Gullick WJ (2005) The epidermal growth factor receptor family. Endocr Relat Cancer 12 Suppl 1: S17-27

延伸閱讀